Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Purified factor VIII.

× No keyword cloud information.

6 in total

Review 1. A practical guide to the evaluation and treatment of hemophilia.

Authors: B Furie; S A Limentani; C G Rosenfield
Journal: Blood Date: 1994-07-01 Impact factor: 22.113

2. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

Authors: R S Schwartz; C F Abildgaard; L M Aledort; S Arkin; A L Bloom; H H Brackmann; D B Brettler; H Fukui; M W Hilgartner; M J Inwood
Journal: N Engl J Med Date: 1990-12-27 Impact factor: 91.245

3. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.

Authors: S V Seremetis; L M Aledort; G E Bergman; R Bona; G Bray; D Brettler; M E Eyster; C Kessler; T S Lau; J Lusher
Journal: Lancet Date: 1993-09-18 Impact factor: 79.321

4. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study.

Authors: J J Goedert; A R Cohen; C M Kessler; S Eichinger; S V Seremetis; C S Rabkin; F J Yellin; P S Rosenberg; L M Aledort
Journal: Lancet Date: 1994-09-17 Impact factor: 79.321

5. The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.

Authors: R de Biasi; A Rocino; E Miraglia; L Mastrullo; A A Quirino
Journal: Blood Date: 1991-10-15 Impact factor: 22.113

6. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

Authors: J M Lusher; S Arkin; C F Abildgaard; R S Schwartz
Journal: N Engl J Med Date: 1993-02-18 Impact factor: 91.245

6 in total